160 related articles for article (PubMed ID: 38282125)
21. Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
Weiss AR; Lyden ER; Anderson JR; Hawkins DS; Spunt SL; Walterhouse DO; Wolden SL; Parham DM; Rodeberg DA; Kao SC; Womer RB
J Clin Oncol; 2013 Sep; 31(26):3226-32. PubMed ID: 23940218
[TBL] [Abstract][Full Text] [Related]
22. Adolescents and young adults with rhabdomyosarcoma treated in the European paediatric Soft tissue sarcoma Study Group (EpSSG) protocols: a cohort study.
Ferrari A; Chisholm JC; Jenney M; Minard-Colin V; Orbach D; Casanova M; Guillen G; Glosli H; van Rijn RR; Schoot RA; Cameron AL; Rogers T; Alaggio R; Ben-Arush M; Mandeville HC; Devalck C; Defachelles AS; Coppadoro B; Bisogno G; Merks JHM
Lancet Child Adolesc Health; 2022 Aug; 6(8):545-554. PubMed ID: 35690071
[TBL] [Abstract][Full Text] [Related]
23. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
Meza JL; Anderson J; Pappo AS; Meyer WH;
J Clin Oncol; 2006 Aug; 24(24):3844-51. PubMed ID: 16921036
[TBL] [Abstract][Full Text] [Related]
24. Clinical and pathological characteristics, treatment outcome and prognostic factors in adult rhabdomyosarcoma: a monocentric retrospective study.
Saadi M; Letaief F; Gabsi A; Mokrani A; Meddeb K; Mezlini A
Pan Afr Med J; 2022; 41():246. PubMed ID: 35734321
[TBL] [Abstract][Full Text] [Related]
25. The prognostic significance of anaplasia in childhood rhabdomyosarcoma: A report from the Children's Oncology Group.
Shenoy A; Alvarez E; Chi YY; Li M; Shern JF; Khan J; Hiniker SM; Granberg CF; Hawkins DS; Parham DM; Teot LA; Rudzinski ER
Eur J Cancer; 2021 Jan; 143():127-133. PubMed ID: 33302115
[TBL] [Abstract][Full Text] [Related]
26. Germline Genetic Testing and Survival Outcomes Among Children With Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Martin-Giacalone BA; Li H; Scheurer ME; Casey DL; Dugan-Perez S; Marquez-Do DA; Muzny D; Gibbs RA; Barkauskas DA; Hall D; Stewart DR; Schiffman JD; McEvoy MT; Khan J; Malkin D; Linardic CM; Crompton BD; Shern JF; Skapek SX; Venkatramani R; Hawkins DS; Sabo A; Plon SE; Lupo PJ
JAMA Netw Open; 2024 Mar; 7(3):e244170. PubMed ID: 38546643
[TBL] [Abstract][Full Text] [Related]
27. Germline genetic variants and pediatric rhabdomyosarcoma outcomes: a report from the Children's Oncology Group.
Martin-Giacalone BA; Richard MA; Scheurer ME; Khan J; Sok P; Shetty PB; Chanock SJ; Li SA; Yeager M; Marquez-Do DA; Barkauskas DA; Hall D; McEvoy MT; Brown AL; Sabo A; Scheet P; Huff CD; Skapek SX; Hawkins DS; Venkatramani R; Mirabello L; Lupo PJ
J Natl Cancer Inst; 2023 Jun; 115(6):733-741. PubMed ID: 36951526
[TBL] [Abstract][Full Text] [Related]
28. Rhabdomyosarcoma of the Breast in Adolescent and Young Adult (AYA) Women.
Audino AN; Setty BA; Yeager ND
J Pediatr Hematol Oncol; 2017 Jan; 39(1):62-66. PubMed ID: 27879537
[TBL] [Abstract][Full Text] [Related]
29. Patterns of chemotherapy-induced toxicities and outcome in children and adolescents with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
Gupta AA; Chi YY; Anderson JR; Lyden E; Weigel B; Arndt C; Meyer WH; Rosenberg A; Hawkins DS
Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28333415
[TBL] [Abstract][Full Text] [Related]
30. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.
Heerema-McKenney A; Wijnaendts LC; Pulliam JF; Lopez-Terrada D; McKenney JK; Zhu S; Montgomery K; Mitchell J; Marinelli RJ; Hart AA; van de Rijn M; Linn SC
Am J Surg Pathol; 2008 Oct; 32(10):1513-22. PubMed ID: 18708938
[TBL] [Abstract][Full Text] [Related]
31. Results of RS-99 protocol for childhood solid tumors.
Cai JY; Tang JY; Pan C; Xu M; Xue HL; Zhou M; Dong L; Ye QD; Jiang H; Shen SH; Chen J
World J Pediatr; 2010 Feb; 6(1):43-9. PubMed ID: 20143210
[TBL] [Abstract][Full Text] [Related]
32. Improved outcome for patients with middle ear rhabdomyosarcoma: a children's oncology group study.
Hawkins DS; Anderson JR; Paidas CN; Wharam MD; Qualman SJ; Pappo AS; Scott Baker K; Crist WM
J Clin Oncol; 2001 Jun; 19(12):3073-9. PubMed ID: 11408504
[TBL] [Abstract][Full Text] [Related]
33. Relationship of DNA ploidy to histology and prognosis in rhabdomyosarcoma. Comparison of flow cytometry and image analysis.
Kilpatrick SE; Teot LA; Geisinger KR; Martin PL; Shumate DK; Zbieranski N; Russell GB; Fletcher CD
Cancer; 1994 Dec; 74(12):3227-33. PubMed ID: 7526971
[TBL] [Abstract][Full Text] [Related]
34. Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma : a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Qualman S; Lynch J; Bridge J; Parham D; Teot L; Meyer W; Pappo A
Cancer; 2008 Dec; 113(11):3242-7. PubMed ID: 18985676
[TBL] [Abstract][Full Text] [Related]
35. Outcome and prognostic variables in childhood rhabdomyosarcoma (RMS) with emphasis on impact of FOXO1 fusions in non-metastatic RMS: experience from a tertiary cancer centre in India.
Ramanathan S; Sisodiya S; Shetty O; Prasad M; Parambil BC; Shah S; Ramadwar M; Khanna N; Laskar S; Qureshi S; Vora T; Chinnaswamy G
Ecancermedicalscience; 2023; 17():1539. PubMed ID: 37138963
[TBL] [Abstract][Full Text] [Related]
36. Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group.
Hingorani P; Missiaglia E; Shipley J; Anderson JR; Triche TJ; Delorenzi M; Gastier-Foster J; Wing M; Hawkins DS; Skapek SX
Clin Cancer Res; 2015 Oct; 21(20):4733-9. PubMed ID: 26473193
[TBL] [Abstract][Full Text] [Related]
37. Clinical characteristics and outcomes of infants compared with children diagnosed with rhabdomyosarcoma: Analysis of surveillance, epidemiology and end results data from 2000 to 2016.
Rees HD; Hills NK; Sabnis AJ; Tulpule AB; Shimotake TK; Goldsby RE
Cancer Rep (Hoboken); 2022 May; 5(5):e1503. PubMed ID: 34254742
[TBL] [Abstract][Full Text] [Related]
38. European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors.
Carli M; Colombatti R; Oberlin O; Bisogno G; Treuner J; Koscielniak E; Tridello G; Garaventa A; Pinkerton R; Stevens M
J Clin Oncol; 2004 Dec; 22(23):4787-94. PubMed ID: 15570080
[TBL] [Abstract][Full Text] [Related]
39. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults.
Dantonello TM; Int-Veen C; Harms D; Leuschner I; Schmidt BF; Herbst M; Juergens H; Scheel-Walter HG; Bielack SS; Klingebiel T; Dickerhoff R; Kirsch S; Brecht I; Schmelzle R; Greulich M; Gadner H; Greiner J; Marky I; Treuner J; Koscielniak E
J Clin Oncol; 2009 Mar; 27(9):1446-55. PubMed ID: 19224858
[TBL] [Abstract][Full Text] [Related]
40. The impact of age on outcome of embryonal and alveolar rhabdomyosarcoma patients. A multicenter study.
Van Gaal JC; Van Der Graaf WT; Rikhof B; Van Hoesel QG; Teerenstra S; Suurmeijer AJ; Flucke UE; Loeffen JL; Sleijfer S; De Bont ES
Anticancer Res; 2012 Oct; 32(10):4485-97. PubMed ID: 23060577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
